Cellular Origins

What Cellular Origins does

Cellular Origins is a UK-based automation manufacturing company founded in January 2023 as a spin-out of TTP Group to address the manufacturing bottleneck that limits approved cell and gene therapies to fewer than 7% of eligible patients. Its flagship product, Constellation, is a configurable, closed, mobile robotic ecosystem that physically and digitally integrates third-party bioprocessing instruments using autonomous mobile robots, proprietary automated sterile tube welding technology (validated at 99.9% reliability across more than 3,000 welds), and automated tube management. The platform is explicitly designed to wrap around existing validated processes and standard tubing, eliminating the need for therapy developers to redevelop their manufacturing workflows as they scale from clinical to commercial production. Demonstrated operational improvements include a 30-fold increase in space efficiency, a 51% reduction in cost of goods, and a 16-fold reduction in labour requirements compared with conventional manual manufacturing.

The company operates a B2B enterprise model targeting pharmaceutical companies with commercial or late-stage cell therapies, cell therapy developers, and CDMOs. Distribution is hybrid: direct enterprise sales augmented by a technology partner ecosystem that includes Cytiva, Fresenius Kabi, Thermo Fisher Scientific, ScaleReady (a Bio-Techne/Fresenius Kabi/Wilson Wolf joint venture), and 3P innovation. Revenue streams derive from platform licensing and technology deployment plus professional integration and validation services, with custom enterprise pricing rather than published list pricing. In July 2024, Cellular Origins acquired the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP from Geoff Hodge to extend capabilities for massively multiplexed and distributed industrial automation in autologous cell therapy.

Following a USD 40 million oversubscribed Series A in December 2025 led by Johnson & Johnson Innovation – JJDC, with participation from Highland Europe, BGF, NYBC Ventures, and founding parent TTP Group, the company is expanding its commercial team and operations at its Melbourn, Cambridge headquarters. Recent strategic moves include collaborations with J&J (autologous CAR-T, June 2025), Thermo Fisher Scientific (June 2025), Cytiva (January 2025), Fresenius Kabi (October 2024), and Immatics (May 2026), alongside a £1M Innovate UK Smart Grant consortium with CGT Catapult and Resolution Therapeutics. The company has 11–50 employees and has won industry recognition including the 2025 Pharmaceutical Technology Excellence Award for Innovation in Manufacturing Automation.

Name

Cellular Origins

Legal name

Cellular Origins Ltd

Website

https://cellularorigins.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Cellular Origins is a UK automation company whose Constellation mobile robotic platform automates cell and gene therapy manufacturing. Founded in 2023 as a TTP Group spin-out, it integrates third-party bioprocessing instruments to help pharma and CGT developers scale production cost-effectively without process redevelopment.

Ownership category

akta.pro rank

Product category

Cell Therapy Manufacturing Automation

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industry

Cell Therapy CDMO (HLAGABAD)

Keywords

• Cell therapy automation
• Robotic bioprocessing
• Advanced therapy manufacturing
• GMP manufacturing platforms
• Sterile fluid handling

Headquarters

HQ city

Melbourn

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Platform Licensing and Technology Deployment: Revenue generated through licensing the Constellation platform technology to cell therapy developers and CDMOs. Includes deployment of robotic automation systems and integration services for scaling cell therapy manufacturing.
2. Professional Services: Implementation, integration, and consulting services for deploying the Constellation platform in customer facilities. Includes facility design, process optimization, and validation support.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Cellular Origins develops and sells Constellation, a closed, configurable, mobile robotic ecosystem for cell and gene therapy manufacturing. The platform combines autonomous mobile robots, proprietary automated sterile tube welding, and a unified digital control layer to physically and digitally integrate third-party bioprocessing instruments from partners such as Cytiva, Fresenius Kabi, Thermo Fisher Scientific, ScaleReady, and 3P innovation, enabling therapy developers and CDMOs to scale from clinical to commercial production without process redevelopment.

Product overview

Cellular Origins offers a single unified platform, Constellation, augmented by acquired technology IP. Constellation is a factory-first, mobile robotic ecosystem that wraps around existing third-party bioprocessing instruments — including those from Fresenius Kabi, Cytiva, Thermo Fisher Scientific, ScaleReady, and 3P innovation — to deliver fully automated, GMP-compliant cell and gene therapy manufacturing. The platform physically and digitally integrates these proven instruments using autonomous mobile robots and automated sterile tube welding, eliminating the need for therapy developers to redevelop their manufacturing processes. The separately acquired ACTIA Platform IP enhances Constellation's capabilities specifically for autologous cell therapy manufacturing, adding massively multiplexed and distributed industrial automation features. Together, these form an end-to-end solution that scales from clinical to commercial production with demonstrated improvements in space efficiency, labour reduction, and cost of goods.

Differentiator

Problem solved

Functional benefit

Brands

• Constellation: A closed, configurable, robotic platform for cell and gene therapy manufacturing that combines aseptic fluid handling technologies with advanced automation, enabling scalable manufacturing without process redevelopment.

Products and services

• Constellation Robotic Platform A closed, configurable, mobile robotic platform that enables scalable, GMP-compliant manufacture of cell and gene therapies by integrating proven third-party bioprocessing instruments through autonomous mobile robots, automated sterile tube welding, and a unified digital control layer, allowing therapy developers to scale from clinical to commercial production without process redevelopment.
• ACTIA Platform IP Acquired intellectual property platform for autologous cell therapy industrial automation, enabling massively multiplexed and distributed industrial manufacturing with selective capacity increases to target process bottlenecks. Sold to cellular therapy developers as part of Cellular Origins' automation offerings.

Quantifiable outcome

• 30-fold increase in space efficiency compared to conventional manual techniques
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered supporting and core.

• ImmaticssupportingTechnology or Integration · 7 May 2026Collaboration to implement Cellular Origins' automated mobile robotic platform within Immatics' cell therapy manufacturing processes. Partnership aims to address manual manufacturing limitations restricting patient access to approved cell therapies, particularly for solid tumor treatments.
• Resolution TherapeuticscoreStrategic or Co-development Partner · 11 July 2025Consortium formed with CGT Catapult to deliver fully automated robotics CGT manufacturing platform. Awarded £1 million Smart Grant from Innovate UK. Resolution provides therapy developer perspective for novel Regenerative Macrophage Therapy products including RTX001 for end-stage liver disease.
• Johnson & JohnsoncoreStrategic or Co-development Partner · 23 June 2025Collaboration to develop a scalable, end-to-end automated platform for autologous CAR-T cell manufacturing. Builds on demonstrated ability to fully automate cell therapy manufacturing processes using validated, off-the-shelf third-party instruments combined with mobile robots and proprietary sterile fluid transfer technology.
• Thermo Fisher ScientificcoreTechnology or Integration · 17 June 2025International collaboration to deliver fully automated, robotic manufacture of cell and gene therapies at industrial scale. Integration of Thermo Fisher's cell culture and processing technology with Constellation platform. First customer installation completed at CGT Catapult's Stevenage facility with VIOS AxD CO2 incubator integration.
• CytivacoreTechnology or Integration · 16 January 2025Collaboration to deliver automated robotic manufacturing capabilities for cell and gene therapies. Integration of Cytiva's Sefia platform with Constellation to enable industrial scale manufacturing without changing processes used during clinical trials. Complete digital interconnection including quality control systems and remote digital controls.
• Fresenius KabicoreTechnology or Integration · 16 October 2024Development agreement to integrate Fresenius Kabi's cell therapy processing technologies into Cellular Origins' Constellation platform. Initial focus on integrating the Cue Cell Processing System for automated, precise small volume cell processing. Goal to create fully automated 24/7 CGT manufacturing at scale with minimal personnel and no process change. Collaboration extended to include Lovo Cell Processing System and future products.
• 3P innovationsupportingTechnology or Integration · 11 September 2024Partnership to integrate 3P innovation's cryoFIL cryovial filling platform within Constellation. Enables automated filling of cryovials within closed and sterile environment. Expands system capabilities for full end-to-end automated solution.
• Cell and Gene Therapy CatapultcoreStrategic or Co-development Partner · 29 May 2024Collaboration to demonstrate universal automation of CGT manufacturing at CGT Catapult's Stevenage Manufacturing Innovation Centre. Physical and digital integration of existing bioprocessing equipment using Constellation. Platform installed at Digital and Automation Testbeds for real-world GMP demonstration and validation.
• ScaleReady (Bio-Techne, Fresenius Kabi, Wilson Wolf joint venture)coreTechnology or Integration · 11 May 2023Partnership to integrate ScaleReady's CGT manufacturing workflow with Cellular Origins' robotic technology. Initial focus on automating ScaleReady's G-Rex platform for standardized and automated interconnections. Eliminates variability in manual connection techniques and advances scalability of CGT manufacturing.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Ori Biotech: Direct competitor developing a fully automated, closed-system cell and gene therapy manufacturing platform targeting the same late-stage/commercial CGT developers as Cellular Origins, with overlapping value propositions around throughput, cost, and process preservation.
• ScaleReady (Bio-Techne / Fresenius Kabi / Wilson Wolf JV): Joint venture offering the G-Rex bioreactor platform and standardised CGT manufacturing workflow; a named Cellular Origins partner for automated interconnections, and a partial competitor in selling 'ready-to-run' cell therapy production systems.

Broad incumbents

• Miltenyi Biotec (Prodigy): Established bioprocessing incumbent offering the Prodigy automated cell processing platform, a closed-system device widely deployed in academic and commercial CGT manufacturing. Overlaps with Cellular Origins on automation of CAR-T and similar workflows but is part of a much broader Miltenyi consumables/instruments portfolio.
• Cytiva: Major bioprocessing OEM and named Cellular Origins partner (Sefia platform integration). Also sells its own end-to-end cell therapy automation, so it is both collaborator and potential competitor across the same customer base.
• Thermo Fisher Scientific: Global life-sciences tools giant and named Cellular Origins partner (Heracell VIOS AxD incubator integration). Operates a large cell therapy services and instruments portfolio that overlaps with Cellular Origins' automation ambition.
• Fresenius Kabi: Cell therapy processing OEM (Cue, Lovo systems) and a core Cellular Origins integration partner. As one of the largest cell therapy instruments suppliers, it competes and collaborates simultaneously with Cellular Origins across the same developers.
• Lonza: Leading CDMO with significant cell and gene therapy manufacturing capacity and proprietary automation investments. Competes with Cellular Origins for the spend of CGT developers seeking both automation platforms and outsourced manufacturing services.

Regional players

• Invetech: Australia-based engineering firm with a long-standing focus on cell therapy automation and contract manufacturing tools; comparable offering for autologous/allogeneic cell processing automation, primarily serving APAC and US customers.

Emerging players

• Vineti: Software/orchestration-focused CGT commercial supply chain platform — adjacent rather than direct hardware competition, but competes for the same 'industrialise CGT manufacturing' budget line within pharma customers.
• Sexton Biotechnologies: Cell therapy fill-finish and cryopreservation automation supplier; tangential overlap with Cellular Origins' cryoFIL-related 3P innovation integration and competes for the same downstream unit-operation automation spend.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cellularorigins
• Xx.com/CellularOrigins

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellular Origins